GeoVax Labs (NASDAQ:GOVX – Get Free Report) and Tango Therapeutics (NASDAQ:TNGX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Institutional and Insider Ownership
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 0.2% of GeoVax Labs shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares GeoVax Labs and Tango Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeoVax Labs | N/A | -743.64% | -394.74% |
| Tango Therapeutics | N/A | -25.75% | -23.36% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeoVax Labs | $2.49 million | 1.06 | -$21.47 million | ($11.34) | -0.03 |
| Tango Therapeutics | $62.38 million | 67.63 | -$101.59 million | ($0.85) | -29.43 |
GeoVax Labs has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
GeoVax Labs has a beta of 3.66, indicating that its share price is 266% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for GeoVax Labs and Tango Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
| Tango Therapeutics | 1 | 2 | 13 | 0 | 2.75 |
GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 41,799.44%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 73.71%. Given GeoVax Labs’ higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Tango Therapeutics.
Summary
Tango Therapeutics beats GeoVax Labs on 9 of the 13 factors compared between the two stocks.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
About Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
